Innovation In Transplantation:
|
|
- Myron Stafford
- 5 years ago
- Views:
Transcription
1 Innovation In Transplantation: Improving outcomes Thomas C. Pearson Department of Surgery Emory Transplant Center CHOA Symposium October 22, 2016
2 Disclosures Belatacept preclinical and clinical trial were supported by Bristol-Myers Squibb I have served on an Advisory Board for Bristol- Myers I will discuss studies of off-label use of belatacept 2
3 Innovation in Transplantation: improving outcomes Current status of clinical transplantation: how we got here Stimulation blockade: concept, mechanism of action and rationale design Belatacept: Pre-Clinical Development Pathway Belatacept: Lessons from Clinical Trials New Opportunities and Unmet Needs
4 Saints Cosmas and Damian The Miracle of the Black Leg 348 AD
5 Nobel Prize in Medicine 1912 Alexis Carrell developed methods for sewing blood vessels together.
6
7
8 Sir Peter Medawar The Nobel Prize in Physiology or Medicine 1960 "for discovery of acquired immunological tolerance"
9 Innovations in Transplantation: Circa 1950 Basic surgical techniques defined Transplants are lost due to an immune response
10 First Kidney Transplant- Dec 1954
11 First Kidney Transplant- Dec 1954 Joseph Murray
12 The Era of Immunosuppression Tweedledee Sir Roy Calne Gertrude Elion George Hitchings Titus Lollipop
13 Evolution of transplant immunosuppression Zand MS. Semin Dial. 2005;18: Improved Immunosuppression Results in Reduced Rejection and Improved Graft Survival
14 Current Agents Calcineurin inhibitors Mycophenolate Mofetil Sirolimus Azathioprine Steroids IL-2R antagonists Anti-lymphocyte antibody preparations alemtuzumab Co-stimulation blockade Leflunomide
15 Kidney Graft Survival Rates PCKD Glomerular Diabetes Hypertension 1 year graft 3 year graft 5 year graft UNOS: National Registry Data Kaplan-Meier Analysis of (Data as of 09/02/2016) 15
16 16
17 Kidney Transplants Performed American Journal of Transplantation pages 11-46, 11 JAN 2016 DOI: /ajt SRTR
18 Region 3 Deceased and Living Donors, 7/1/2006-6/30/ Number of Donors Deceased Donor 0 Living Donor NOTE: 2007=7/1/2006-6/30/2007; 2008=7/1/2007-6/30/2008; 2009=7/1/2008-6/30/2009; 2010=7/1/2009-6/30/2010; 2011=7/1/2010-6/30/2011; 2012=7/1/2011-6/30/2012; 2013=7/1/2012-6/30/2013; 2014=7/1/2013-6/30/2014; 2015=7/1/2014-6/30/2015; 2016=7/1/2015-6/30/2016 Year
19 19
20 Adult Kidney Transplant Wait List American Journal of Transplantation pages 11-46, 11 JAN 2016 DOI: /ajt SRTR
21 Kidney Median Time to Transplant American Journal of Transplantation pages 11-46, 11 JAN 2016 DOI: /ajt SRTR
22 Immunosuppression for Renal Transplantation Basiliximab Thymoglobulin Calcineurin Inhibitor Mycophenolate Steroids Time
23 Lodhi and Meier-Kriesche, 2011
24 Improving long-term outcomes and healthspan: a daunting but worthy goal Graft Survival (%) % Survival (Half Life) Highly complex regimens Demanding follow-up 20 Mechanism-based toxicity Years High blood pressure Diabetes Nephrotoxicity Risk of DSA Non-adherence Meier-Kriesche AJT 2004; 4: 1289
25 Causes of Graft Loss Causes of Graft Loss >6 Months Glomerulonephritis 6% Other 5% Chronic rejection 36% Death with function 50% Reference: Ojo AO. Kidney Int 2000;57:
26 Causes of Death with a Functioning Graft USRDS 2009 Adult Renal Transplants
27 Improving Long-term Outcomes a daunting but worthy goal 100 Graft Survival (%) 80 Why is 60it so hard to improve long-term survival and healthspan? 50% Survival (Half Life) 40 Highly complex regimens Long-term trials are logistically and financially impractical. Demanding follow-up SRTR, CMS and Centers of Excellence drive improvement in short-term outcomes Years Meier-Kriesche AJT 2004; 4: 1289 Mechanism-based toxicity Pressures to reduce acute care cost can compete with strategies to improve long-term outcomes. High blood pressure Diabetes Nephrotoxicity Much (most) of long care is given outside of transplant centers Non-adherence Drug-sparing risk of DSA And yet, we the transplant community must design and deliver the solutions
28 Innovations in Transplantation: Circa 2000 Short-term results are very good Long-term results not improving The wait list is long and getting longer
29 Immunosuppression: Goals Maintain efficacy acute rejection Improve toxicity profile Improved long-term outcomes
30 Transplant Immunology 101 T cells play a central role in graft rejection Co-stimulation pathways critical for T cell function
31 CD28 a Critical Costimulatory Pathway B7-1 (CD80) B7-2 (CD86) CD28 CTLA4 Enhanced T cell survival Activate bioenergetics MHC TCR Cytokine synthesis
32
33 Discovery of Co-stimulation Maturation renders DC 100-fold more potent T cell activators Nobel Prize in Medicine, 2011
34 Development of CTLA4-Ig Structure and Function of B7, CD28, and CLTA4 begin to be elucidated CLTA4-Ig in born Peter Linsley Ed Clark Craig Thompson Jeff Bluestone
35 Development of a CTLA-4 Fusion Protein to Block CD28 Costimulation CTLA-4 CTLA-4 Ig CTLA-4 Ig Human IgG1 37
36 Costimulation moves from biology to therapeutic target CTLA4-Ig Drug candidate Costimulation blocker
37 Rhesus Kidney Transplant Model Yerkes Primate Research Center
38 CD28 Blockade: Pre-clinical model CTLA4-Ig Control Time (days) CTLA4-Ig minimal effect on survival
39 Effective for treatment of rheumatoid arthritis T cell-mediated autoimmune disorder Large safety experience with long-term administration
40 Belatacept: Rational Design A29 L104 CTLA4 Extracellular Domain Silent IgG1 Tail High affinity CTLA4-Ig variant Increased biologic potency Larsen, Pearson et al AJT 2005
41 10-fold greater inhibition of T cell responses in vitro Serum Cr Prolonged Transplant survival in CNI-inhibitor-free regimens Basilximab Basiliximab Belatacept Larsen et al Am J Trans 2005 Treatment ends
42 Belatacept Core Development Program Renal Transplant (N = 1427) Phase II IM (N=218) Proof of concept Potential alternative to CNI Phase III IM BENEFIT (N=666) Standard criteria donors IM BENEFIT-EXT (N=543) Extended criteria donors >900 renal transplant recipients received belatacept
43 BENEFIT and BENFIT-EXT Study Design De Novo therapy in Kidney Transplant recipients Prospective, randomized, international, multi-center Superior renal function, non-inferior rejection control Primary endpoint Secondary endpoints Randomization 6 months 12 months 24 months 36 months Belatacept MI 10 mg/kg 5 mg/kg every 4 weeks DAY Belatacept LI 10 mg/kg 5 mg/kg every 4 weeks DAY Cyclosporine ng/ml ng/ml DAY 1 28 All patients received basiliximab induction, mycophenolate mofetil, and corticosteroids Only CsA patients: T-cell depleting agents permitted for anticipated DGF 47
44 Belatacept Maintains Superior Renal Function BENEFIT: cgfr Slope Bela MI Bela LI CsA from CsA from CsA from CsA ITT analysis w/ imputation. Patients with death or graft loss imputed as cgfr = BENEFIT 48
45 Belatacept Improves Cardiovascular & Metabolic Profiles Lower Blood Pressure with fewer medications Favorable lipid profiles with fewer medications New Onset Diabetes lower at 12 mo, not significant at 24 or 36 months
46 Allograft Rejection and its consequences
47 Acute Rejection by Year 3 Belatacept MI Belatacept LI CsA BENEFIT 24% 17% 10% BENEFIT-EXT 18% 19% 16% 52
48 Comprehensive Benefit-Risk Assessment Absolute Difference between Belatacept LI and CsA (%) Death/Graft Loss Belatacept better -3.2 CsA better Death Rejection Rejection w/ckd 4/5 CKD Stage 4/5 NODAT Uncontrolled HTN Uncontrolled Dyslipidemia Serious Infections Malignancy PTLD (EBV+) Pooled Core Studies
49 Belatacept: path to approval Concept: Belatacept evaluated as alternative to cyclosporine Program Objectives Maintain short-term survival Non-inferior for control of rejection Superiority for renal function Phase III Trials begin 2005 FDA Panel Review 2009 Belatacept FDA Approval June 15, 2011 First Recipient receives Belatacept standard of care July 26, 2011 Phase II Transplant Trial 2001
50 Belatacept 1.0/1.1 Protocol (2011) Belatacept Intensity of Exposure Maintenance Induction Mycophenolate Prednisone (5) Basiliximab Time
51 Belatacept 1.0 We have a problem! 100 Freedom from Rejection 100 Graft Survival % 40 Bela 1.0/1.1 (N=98) Tac (N=206) *p=0.57 Bela 1.0/1.1 (N=98) Tac (N=206) Days Months
52 egfr of Tac and Bela 1.0/1.1 Intent-to-Treat Patients egfr Tac Bela 1.0/ Month 1 mo 2 mo 3 mo 6 mo 9 mo 12 mo 24 mo 36 mo 48 mo Bela(N=97) Tac(N=205)
53 Continuous improvement cycle Belatacept Adjust Protocol Design patient cycles Monitor Implement
54 Risk of Rejection Tacrolimus Induction Patients at risk of early post-transplant rejection Belatacept months post-transplant
55 Belatacept Protocols Intensity of Exposure Maintenance Induction Belatacept De-intensified Mycophenolate Prednisone (5) Basiliximab Tacrolimus Time
56 Freedom from Rejection 100 Belatacept Belatacept/Tac short Belatacept/Tac extended % 60 %
57 Belatacept vs Tacrolimus: All Patients 100 Graft Survival 70 Renal Function (egfr) Tac 80 Bela Bela (N=518) 40 Tac (N=205) Years Months
58 Belatacept associated with lower rates donor-specific Antibody *p=0.002 % Freedom from DSA Belatacept Tacrolimus Months
59 January J January 28, 2016
60 Rates of Death or Graft Loss
61 Kidney Graft Function
62 Innovation in transplantation: Circa 2016 Better safety profile Improved renal function Higher acute rejection rate More severe rejection pathology Acute Rejection Rates Percent Patients with Acute Rejection Cyclosporine Belatacept
63 Belatacept On Going Clinical Trials Conversion Trial Thymoglobulin Induction
64 Moving forward: The next generation of costimulation blockers How can we optimize CD28-based costimulation blockade? Improve upon current CD28 costimulation blockade reagents Combine current CD28 blockers with novel therapeutics to improve efficacy
65 Krummey and Ford Frontiers Immunol 2012
66 Genetically Engineered Donor Organs Normally organs from other species are promptly rejected due to key protein differences Making Pig Organs more human-like by Knocking Out key rejection molecules Previous reports average time to rejection 2-3 weeks Emory Xeno-Kidney Project- >300 days, longest ever reported
67 Doube Knockout Donor Pig Gal -/-, β4gal -/-
68 Needs Clinical Application Application Discovery Discovery Translation Translation
69 78
Belatacept: An Opportunity to Personalize Immunosuppression? Andrew Adams MD/PhD Emory Transplant Center
Belatacept: An Opportunity to Personalize Immunosuppression? Andrew Adams MD/PhD Emory Transplant Center Disclosure Research Funding from BMS. Learning Objectives -Define belatacept-resistant rejection
More informationWhy Do We Need New Immunosuppressive Agents
Why Do We Need New Immunosuppressive Agents 1 Reducing acute rejection rates has not transplanted into better long-term graft survival Incidence of early acute rejection episodes by era Relative risk for
More informationOverview of New Approaches to Immunosuppression in Renal Transplantation
Overview of New Approaches to Immunosuppression in Renal Transplantation Ron Shapiro, M.D. Professor of Surgery Surgical Director, Kidney/Pancreas Transplant Program Recanati/Miller Transplantation Institute
More informationLiterature Review: Transplantation July 2010-June 2011
Literature Review: Transplantation July 2010-June 2011 James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver Kidney Transplant Top 10 List: July Kidney
More informationLiterature Review Transplantation
Literature Review 2010- Transplantation Alexander Wiseman, M.D. Associate Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas Transplant Programs University of
More informationVictims of success: Do we still need clinical trials? Robert S. Gaston, MD CTI Clinical Trials and Consulting University of Alabama at Birmingham
Victims of success: Do we still need clinical trials? Robert S. Gaston, MD CTI Clinical Trials and Consulting University of Alabama at Birmingham Disclosure Employee: CTI Clinical Trials and Consulting
More informationBelatacept: An Update of Ongoing Clinical Trials
Belatacept: An Update of Ongoing Clinical Trials Michael D. Rizzari, MD University of Wisconsin Madison School of Medicine and Public Health, Madison, Wisconsin Abstract Belatacept is a fusion protein
More informationControversies in Renal Transplantation. The Controversial Questions. Patrick M. Klem, PharmD, BCPS University of Colorado Hospital
Controversies in Renal Transplantation Patrick M. Klem, PharmD, BCPS University of Colorado Hospital The Controversial Questions Are newer immunosuppressants improving patient outcomes? Are corticosteroids
More informationBetter than Google- Click on Immunosuppression Renal Transplant. David Landsberg Oct
Better than Google- Click on Immunosuppression Renal Transplant David Landsberg Oct 3 2008 OUTLINE History of Immunosuppression Trends in Immunosupression FK vs CYA Steroid Minimization CNI Avoidance Sirolimus
More informationWhy we need a new paradigm in immunosuppression USHERING A NEW ERA OF IMMUNOSUPPRESSION. Causes of death and graft loss after kidney transplantation
USHERING A NEW ERA OF IMMUNOSUPPRESSION Flavio Vincenti 45 35 AR 3 (%) 25 15 5 35.7 Why we need a new paradigm in immunosuppression Incidence of early acute rejection episodes ( 6 months) 43.7 27.4 17.9
More informationKidney transplantation: into the future with belatacept
Kidney transplantation: into the future with belatacept Clin. Invest. (2012) 2(12), 1171 1176 Allogenic organ transplantations are limited by drug-associated toxicity and the occurrence of antibody-mediated
More informationTolerance Induction in Transplantation
Tolerance Induction in Transplantation Reza F. Saidi, MD, FACS, FICS Assistant Professor of Surgery Division of Organ Transplantation Department of Surgery University of Massachusetts Medical School Percent
More informationImmunopathology of T cell mediated rejection
Immunopathology of T cell mediated rejection Ibrahim Batal MD Columbia University College of Physicians & Surgeons New York, NY, USA Overview Pathophysiology and grading of TCMR TCMR is still a significant
More informationPediatric Kidney Transplantation
Pediatric Kidney Transplantation Vikas Dharnidharka, MD, MPH Associate Professor Division of Pediatric Nephrology Conflict of Interest Disclosure Vikas Dharnidharka, MD, MPH Employer: University of Florida
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 30 November 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 30 November 2011 NULOJIX 250 mg, powder for concentrate for solution for infusion B/1 (CIP code: 580 415-7) B/2 (CIP
More informationTen-year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4-weekly or 8-weekly
Ten-year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4-weekly or 8-weekly F. Vincenti, University of California, San Francisco G. Blancho, University
More informationSELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80%
SELECTED ABSTRACTS The following are summaries of selected posters presented at the American Transplant Congress on May 5 9, 2007, in San Humar A, Gillingham KJ, Payne WD, et al. Review of >1000 kidney
More informationEuropean Risk Management Plan. Measures impairment. Retreatment after Discontinuation
European Risk Management Plan Table 6.1.4-1: Safety Concern 55024.1 Summary of Risk Minimization Measures Routine Risk Minimization Measures Additional Risk Minimization Measures impairment. Retreatment
More informationLiver Transplant Immunosuppression
Liver Transplant Immunosuppression Michael Daily, MD, MS, FACS Surgical Director, Kidney and Pancreas Transplantation University of Kentucky Medical Center Disclosures No financial disclosures I will be
More informationPost Transplant Immunosuppression: Consideration for Primary Care. Sameh Abul-Ezz, M.D., Dr.P.H.
Post Transplant Immunosuppression: Consideration for Primary Care Sameh Abul-Ezz, M.D., Dr.P.H. Objectives Discuss the commonly used immunosuppressive medications and what you need to know to care for
More informationSteroid Minimization: Great Idea or Silly Move?
Steroid Minimization: Great Idea or Silly Move? Disclosures I have financial relationship(s) within the last 12 months relevant to my presentation with: Astellas Grants ** Bristol Myers Squibb Grants,
More informationOBJECTIVES. Phases of Transplantation and Immunosuppression
Transplant and Immunosuppression: Texas Transplant Center April 29, 2017 Regina L. Ramirez, Pharm.D., BCPS PGY1 Pharmacy Residency Program Director Clinical Practice Specialist Solid Organ Transplant and
More informationChapter 6: Transplantation
Chapter 6: Transplantation Introduction During calendar year 2012, 17,305 kidney transplants, including kidney-alone and kidney plus at least one additional organ, were performed in the United States.
More informationTRANSPLANT IMMUNOLOGY. Shiv Pillai Ragon Institute of MGH, MIT and Harvard
TRANSPLANT IMMUNOLOGY Shiv Pillai Ragon Institute of MGH, MIT and Harvard Outline MHC / HLA Direct vs indirect allorecognition Alloreactive cells: where do they come from? Rejection and Immunosuppression
More informationChronic Kidney Disease & Transplantation. Paediatrics : 2004 FRACP
Chronic Kidney Disease & Transplantation Paediatrics : 2004 FRACP ANZDATA Registry Mode of First Treatment - Paediatric 14 12 10 8 6 4 2 0 0-4 y 5-9 y 10-14 y 15-19 y Hospital CAPD Hospital HD Hospital
More informationWhat is the Best Induction Immunosuppression Regimen in Kidney Transplantation? Richard Borrows: Queen Elizabeth Hospital Birmingham
What is the Best Induction Immunosuppression Regimen in Kidney Transplantation? Richard Borrows: Queen Elizabeth Hospital Birmingham SYMPHONY Study Ekberg et al. NEJM 2008 Excluded: DCD kidneys; CIT>30hours;
More informationAlemtuzumab-based induction treatment versus basiliximab based induction treatment in kidney transplantation (the 3C Study): a randomised trial
Alemtuzumab-based induction treatment versus basiliximab based induction treatment in kidney transplantation (the 3C Study): a randomised trial Journal club Feb 2014 Background and Rationale Despite substantial
More informationTransplantation: Year in Review
Transplantation: Year in Review Alexander Wiseman, MD Medical Director, Kidney and Pancreas Transplant Program Associate Professor, Division of Renal Diseases and Hypertension University of Colorado Outline:
More informationCase Report Beneficial Effect of Conversion to Belatacept in Kidney-Transplant Patients with a Low Glomerular-Filtration Rate
Case Reports in Transplantation, Article ID 190516, 4 pages http://dx.doi.org/10.1155/2014/190516 Case Report Beneficial Effect of Conversion to Belatacept in Kidney-Transplant Patients with a Low Glomerular-Filtration
More informationImmunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Immunosuppressants Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressive Agents Very useful in minimizing the occurrence of exaggerated or inappropriate
More informationAmerican Journal of Transplantation 2009; 9 (Suppl 3): S1 S157 Wiley Periodicals Inc.
American Journal of Transplantation 2009; 9 (Suppl 3): S1 S157 Wiley Periodicals Inc. 2009 The Authors Journal compilation 2009 The American Society of Transplantation and the American Society of Transplant
More informationTransplantation in Australia and New Zealand
Transplantation in Australia and New Zealand Matthew D. Jose MBBS (Adel), FRACP, FASN, PhD (Monash), AFRACMA Professor of Medicine, UTAS Renal Physician, Royal Hobart Hospital Overview CKD in Australia
More informationKidney transplantation 2016: current status and potential challenges
Kidney transplantation 2016: current status and potential challenges 15/12/2016 BVN-SBN : State-of-the-Art on Kidney Transplantation Patrick Peeters Ghent University Hospital, Belgium Challenges in 2016
More informationPotential Catalysts in Therapeutics
LIVER TRANSPLANTATION 20:S22 S31, 2014 SUPPLEMENT Potential Catalysts in Therapeutics Bruce A. Luxon Division of Gastroenterology-Hepatology, University of Iowa, Iowa City, IA Received July 23, 2014; accepted
More informationProgress in Pediatric Kidney Transplantation
Send Orders for Reprints to reprints@benthamscience.net The Open Urology & Nephrology Journal, 214, 7, (Suppl 2: M2) 115-122 115 Progress in Pediatric Kidney Transplantation Jodi M. Smith *,1 and Vikas
More informationConsidering the early proactive switch from a CNI to an mtor-inhibitor (Case: Male, age 34) Josep M. Campistol
Considering the early proactive switch from a CNI to an mtor-inhibitor (Case: Male, age 34) Josep M. Campistol Patient details Name DOB ESRD Other history Mr. B.I.B. 12 January 1975 (34yo) Membranous GN
More informationChronic Kidney Disease (CKD) Stages. CHRONIC KIDNEY DISEASE Treatment Options. Incident counts & adjusted rates, by primary diagnosis Figure 2.
Chronic Kidney Disease (CKD) Stages Stage 1 GFR > 90 (evidence of renal disease) Stage 2 GFR 60-89 Stage 3 GFR 30-59 Stage 4 GFR 15-29 Stage 5 GFR
More informationDate: 23 June Context and policy issues:
Title: Basiliximab for Immunosuppression During a Calcineurin Inhibitor Holiday in Renal Transplant Patients with Acute Renal Dysfunction: Guidelines for Use and a Clinical and Cost-Effectiveness Review
More informationCAMPATH INDUCTION IN RENAL TRANSPLANTATION. by Kakit Edmond Chan. Thesis is submitted for the degree of MD [Res] of Imperial College London
CAMPATH INDUCTION IN RENAL TRANSPLANTATION by Kakit Edmond Chan Thesis is submitted for the degree of MD [Res] of Imperial College London Department of Medicine Imperial College London kkchan 1 Abstract
More informationCopyright information:
Posttransplant reduction in preexisting donor-specific antibody levels after belataceptversus cyclosporine-based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT-EXT Robert A Bray, Emory University
More informationEfficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function
ArtIcle Efficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function Guodong Chen, 1 Jingli Gu, 2 Jiang Qiu, 1 Changxi
More informationLong-Term Belatacept Exposure Maintains Efficacy and Safety at 5 Years: Results From the Long-Term Extension of the BENEFIT Study
American Journal of Transplantation 2013; 13: 2875 2883 Wiley Periodicals Inc. C Copyright 2013 The Authors. American Journal of Transplantation Published by Wiley Periodicals, Inc. on behalf of American
More informationJadranka Buturović-Ponikvar Department of Nephrology, University Medical Center, Ljubljana, Slovenia
Jadranka Buturović-Ponikvar Department of Nephrology, University Medical Center, Ljubljana, Slovenia Hemodialysis or kidney transplantation what is better? Jadranka Buturović-Ponikvar Department of Nephrology,
More informationHeart Transplantation ACC Middle East Conference Dubai UAE October 21, 2017
Heart Transplantation ACC Middle East Conference Dubai UAE October 21, 2017 Randall C Starling MD MPH FACC FAHA FESC FHFSA Professor of Medicine Kaufman Center for Heart Failure Department of Cardiovascular
More informationIntruduction PSI MODE OF ACTION AND PHARMACOKINETICS
Multidisciplinary Insights on Clinical Guidance for the Use of Proliferation Signal Inhibitors in Heart Transplantation Andreas Zuckermann, MD et al. Department of Cardio-Thoracic Surgery, Medical University
More informationclevelandclinic.org/transplant
carolyn spiotta Pancreas/Kidney Transplant Recipient I feel so fortunate and thankful that I have received a second chance at life. Carolyn Spiotta, 44, Pittsburgh. Carolyn needed a new pancreas and kidney
More informationRyszard Grenda: Steroid-Free Pediatric Transplantation. Early Steroid Withdrawal in Pediatric Renal Transplantation
Trends in Transplant. 2011;5:115-20 Ryszard Grenda: Steroid-Free Pediatric Transplantation Early Steroid Withdrawal in Pediatric Renal Transplantation Ryszard Grenda Department of Nephrology, Kidney Transplantation
More informationASSESSMENT OF THE PAEDIATRIC NEEDS IMMUNOLOGY DISCLAIMER
European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref.: EMEA/381922/2006 ASSESSMENT OF THE PAEDIATRIC NEEDS IMMUNOLOGY DISCLAIMER The Paediatric Working Party
More informationImmunosuppression is now manageable in the
EVOLVING STRATEGIES FOR IMMUNOSUPPRESSION IN RENAL TRANSPLANTATION: A REVIEW OF RECENT CLINICAL TRIALS* Stephen J. Tomlanovich, MD, Thomas C. Pearson, MD, DPhil, and Lorenzo Gallon, MD ABSTRACT When using
More informationLong term liver transplant management
Long term liver transplant management Dr Bill Griffiths Cambridge Liver Unit Royal College of Physicians 5.7.17 Success of Liver Transplantation Current survival, 1 st elective transplant: 1 yr survival
More informationKidney Transplant Outcomes In Elderly Patients. Simin Goral MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania
Kidney Transplant Outcomes In Elderly Patients Simin Goral MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania Case Discussion 70 year old Asian male, neuropsychiatrist, works full
More informationAre two better than one?
Are two better than one? Disclosures Ryutaro Hirose, MD Professor in Clinical Surgery University of California, San Francisco I have no relevant disclosures related to this presentation The PROBLEM There
More informationTransplantation simplified. Dr Jasna Macanovic Consultant Nephrologist Wessex Renal and Transplant Services Portsmouth, UK
Transplantation simplified Dr Jasna Macanovic Consultant Nephrologist Wessex Renal and Transplant Services Portsmouth, UK HISTORY The first successful kidney transplant was performed in 1954 between identical
More informationFor Immediate Release Contacts: Jenny Keeney Astellas US LLC (847)
For Immediate Release Contacts: Jenny Keeney Astellas US LLC (847) 317-5405 Lauren McDonnell GolinHarris (312) 729-4233 ASTELLAS RECEIVES FDA APPROVAL FOR USE OF PROGRAF (TACROLIMUS) IN CONJUNCTION WITH
More informationT Lymphocyte Activation and Costimulation. FOCiS. Lecture outline
1 T Lymphocyte Activation and Costimulation Abul K. Abbas, MD UCSF FOCiS 2 Lecture outline T cell activation Costimulation, the B7:CD28 family Inhibitory receptors of T cells Targeting costimulators for
More informationNephrology Grand Rounds
Nephrology Grand Rounds PTLD in Kidney Transplantation Charles Le University of Colorado 6/15/12 Objectives Background Pathogenesis Epidemiology and Clinical Manifestation Incidence Risk Factors CNS Lymphoma
More information2017 CST-Astellas Canadian Transplant Fellows Symposium. Management of Renal Dysfunction in Extra Renal Transplants
2017 CST-Astellas Canadian Transplant Fellows Symposium Management of Renal Dysfunction in Extra Renal Transplants Jeffrey Schiff, MD Dr. Jeffrey Schiff is an Assistant Professor of Medicine at the University
More informationSolid Organ Transplantation 1. Chapter 55. Solid Organ Transplant, Self-Assessment Questions
Solid Organ Transplantation 1 Chapter 55. Solid Organ Transplant, Self-Assessment Questions Questions 1 to 9 are related to the following case: A 38-year-old white man is scheduled to receive a living-unrelated
More information1980s-1990s1990s 9/24/2010. David Wojciechowski and. Mary Kennedy-Breiner. Laurie Carlson. Janine Sabatte- Caspillo
Factors Influencing Length of Stay: 1980s-1990s1990s Mail the Get Well Cards Home!! Effectively Managing Shorter Length of Stays David Wojciechowski and Higher rejection rates Longer duration of induction
More informationKIDNEY TRANSPLANTATION FOR THE INTERNIST. Marc Richards MD South Florida Kidney Disease and Hypertension Specialists BRRH Grand Rounds 5.8.
KIDNEY TRANSPLANTATION FOR THE INTERNIST Marc Richards MD South Florida Kidney Disease and Hypertension Specialists BRRH Grand Rounds 5.8.2018 Goal of Lecture: OUTLINE CKD -> ESRD Workup for Transplant
More informationCurrent Trends in Kidney Transplantation: The Role of Nonadherence
Current Trends in Kidney Transplantation: The Role of Nonadherence Donald E. Hricik, MD Professor of Medicine Case Western Reserve University Chief of the Division of Nephrology and Hypertension Medical
More informationImmunosuppressants, Organ Transplants, and Potential of Regenerative Medicine: Market Size, Competitive Landscape, and Pipeline Analysis
Immunosuppressants, Organ Transplants, and Potential of Regenerative Medicine: Market Size, Competitive Landscape, and Pipeline Analysis Introduction This report examines treatment protocols evolved over
More informationKidney and Pancreas Transplantation in the United States,
American Journal of Transplantation 2006; 6 (Part 2): 1153 1169 Blackwell Munksgaard No claim to original US government works Journal compilation C 2006 The American Society of Transplantation and the
More informationShould red cells be matched for transfusions to patients listed for renal transplantation?
Should red cells be matched for transfusions to patients listed for renal transplantation? Dr M.Willicombe Imperial College Renal and Transplant Centre, Hammersmith Hospital Should red cells be matched
More informationPleiotropic effects of mtor inhibitors : cardiovascular and cancer. Dr Paolo Malvezzi Clinique de Néphrologie CHU Grenoble
Pleiotropic effects of mtor inhibitors : cardiovascular and cancer Dr Paolo Malvezzi Clinique de Néphrologie CHU Grenoble Tehran August 2016 Why this topic? Since last year very little news in the immunosuppressive
More informationLionel Rostaing, Nassim Kamar: Alefacept and Transplantation. Alefacept Treatment in the Setting of Transplantation
Trends in Transplant. 2014;8:35-40 Lionel Rostaing, Nassim Kamar: Alefacept and Transplantation Alefacept Treatment in the Setting of Transplantation Lionel Rostaing and Nassim Kamar Department of Nephrology
More informationPrecision Medicine and not Individualized Therapy is Required for Successful Novel Drug Development
Precision Medicine and not Individualized Therapy is Required for Successful Novel Drug Development 1 Disclosures F Vincenti University of California San Francisco, San Francisco, United States I have
More informationLe migliori strategie immunosoppressive per il paziente con re-trapianto Prof. Maurizio Salvadori FIRENZE
Le migliori strategie immunosoppressive per il paziente con re-trapianto Prof. Maurizio Salvadori FIRENZE Best Therapy for Kidney Re- Transplantation? PREVENTION!!!! Registries CTS OPTN UNOS USRDS SRTR
More informationFellows Conference 01/21/2016
Fellows Conference 01/21/2016 Outline Basics of transplantation Benefits of transplantation Immunosuppressive medications Anatomy of Renal Transplantation Recipient Selection General medical condition.
More informationChapter 4: Steroid-resistant nephrotic syndrome in children Kidney International Supplements (2012) 2, ; doi: /kisup.2012.
http://www.kidney-international.org & 2012 KDIGO Chapter 4: Steroid-resistant nephrotic syndrome in children Kidney International Supplements (2012) 2, 172 176; doi:10.1038/kisup.2012.17 INTRODUCTION This
More informationPost-Transplant Monitoring for the Development of Anti-Donor HLA Antibodies
Post-Transplant Monitoring for the Development of Anti-Donor HLA Antibodies Lorita M Rebellato, Ph.D., D (ABHI) Associate Professor Department of Pathology The Brody School of Medicine at ECU Scientific
More informationBelatacept and Long-Term Outcomes in Kidney Transplantation
Original Article Belatacept and Long-Term Outcomes in Kidney Transplantation Flavio Vincenti, M.D., Lionel Rostaing, M.D., Ph.D., Joseph Grinyo, M.D., Ph.D., Kim Rice, M.D., Steven Steinberg, M.D., Luis
More informationTransplant Overview. Timothy J. Schroeder President and CEO CTI Clinical Trial and Consulting Services November 10, 2005
Transplant Overview Timothy J. Schroeder President and CEO CTI Clinical Trial and Consulting Services November 10, 2005 CTI Clinical Trial and Consulting Services Drug Development Company focused in key
More informationAntigen Presentation and T Lymphocyte Activation. Abul K. Abbas UCSF. FOCiS
1 Antigen Presentation and T Lymphocyte Activation Abul K. Abbas UCSF FOCiS 2 Lecture outline Dendritic cells and antigen presentation The role of the MHC T cell activation Costimulation, the B7:CD28 family
More informationRenal Transplant Past Present and Future David Landsberg
2012 Renal Transplant Past Present and Future David Landsberg Outline Changing pattern of Donors Types of Donors Allocation Results Challenges in the Elderly LDPE Transplants By Year LD LRD LUD NDAD DD
More informationThe common premise for immunosuppressive
therapy update Current trends in immunosuppressive therapies for renal transplant recipients The common premise for immunosuppressive therapies in kidney transplantation is to use multiple agents to work
More informationThis study is currently recruiting participants.
A Two Part, Phase 1/2, Safety, PK and PD Study of TOL101, an Anti-TCR Monoclonal Antibody for Prophylaxis of Acute Organ Rejection in Patients Receiving Renal Transplantation This study is currently recruiting
More informationChapter 22: Hematological Complications
Chapter 22: Hematological Complications 22.1: Perform a complete blood count at least (Not Graded): daily for 7 days, or until hospital discharge, whichever is earlier; two to three times per week for
More informationBK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy
BK virus infection in renal transplant recipients: single centre experience Dr Wong Lok Yan Ivy Background BK virus nephropathy (BKVN) has emerged as an important cause of renal graft dysfunction in recent
More informationT Cell Activation, Costimulation and Regulation
1 T Cell Activation, Costimulation and Regulation Abul K. Abbas, MD University of California San Francisco 2 Lecture outline T cell antigen recognition and activation Costimulation, the B7:CD28 family
More informationSerum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant
SDC, Patients and Methods Complement-dependent lymphocytotoxic crossmatch test () Serum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant donor-specific CXM was
More informationTransplant Nephrology Update: Focus on Outcomes and Increasing Access to Transplantation
Transplant Nephrology Update: Focus on Outcomes and Increasing Access to Transplantation Titte R Srinivas, MD, FAST Medical Director, Kidney and Pancreas Transplant Programs Objectives: Describe trends
More informationStrategies for Desensitization
Strategies for Desensitization Olwyn Johnston MB, MRCPI, MD, MHSc BC Nephrology Day October 8 th 2010 Pre-transplant crossmatch (CMX) with donor lymphocytes has been standard of practice Positive CDC CXM
More informationRe: Final Appraisal Determination - Immunosuppressive therapy for kidney transplant in adults (review of technology appraisal guidance 85)
January 19 th, 2016 Dr Margaret Helliwell Vice chair National Institute for Health and Care Excellence 10 Spring Gardens London SW1A 2BU Dear Margaret Re: Final Appraisal Determination - Immunosuppressive
More informationJames E. Cooper, M.D. Assistant Professor, University of Colorado at Denver Division of Renal Disease and Hypertension, Kidney and PancreasTransplant
James E. Cooper, M.D. Assistant Professor, University of Colorado at Denver Division of Renal Disease and Hypertension, Kidney and PancreasTransplant Program Has no real or apparent conflicts of interest
More informationNAPRTCS Annual Transplant Report
North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 2010 Annual Transplant Report This is a privileged communication not for publication. TABLE OF CONTENTS PAGE I INTRODUCTION 1 II
More informationInduction Therapy for Kidney Transplant Recipients: Do We Still Need Anti-IL2 Receptor Monoclonal Antibodies?
American Journal of Transplantation 2017; 17: 22 27 Wiley Periodicals Inc. Minireview 2016 The Authors. American Journal of Transplantation published by Wiley Periodicals, Inc. on behalf of American Society
More informationNAPRTCS Annual Transplant Report
North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 2014 Annual Transplant Report This is a privileged communication not for publication. TABLE OF CONTENTS PAGE II TRANSPLANTATION Section
More informationImmunosuppression: evolution in practice and trends,
American Journal of Transplantation 25; 5 (Part 2): 874 886 Blackwell Munksgaard Blackwell Munksgaard 25 Immunosuppression: evolution in practice and trends, 1993 23 Ron Shapiro a,, James B. Young b, Edgar
More informationThree-Year Outcomes from BENEFIT, a Randomized, Active-Controlled, Parallel-Group Study in Adult Kidney Transplant Recipients
American Journal of Transplantation 2012; 12: 210 217 Wiley Periodicals Inc. C Copyright 2011 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/j.1600-6143.2011.03785.x
More informationTransplant Hepatology
Transplant Hepatology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified
More informationEmerging Drug List EVEROLIMUS
Generic (Trade Name): Manufacturer: Everolimus (Certican ) Novartis Pharmaceuticals NO. 57 MAY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence: For use with cyclosporine
More informationBK Virus (BKV) Management Guideline: July 2017
BK Virus (BKV) Management Guideline: July 2017 BK virus has up to a 60-80% seroprevalence rate in adults due to a primary oral or respiratory exposure in childhood. In the immumocompromised renal transplant
More informationReduced graft function (with or without dialysis) vs immediate graft function a comparison of long-term renal allograft survival
Nephrol Dial Transplant (2006) 21: 2270 2274 doi:10.1093/ndt/gfl103 Advance Access publication 22 May 2006 Original Article Reduced graft function (with or without dialysis) vs immediate graft function
More information3/6/2017. Prevention of Complement Activation and Antibody Development: Results from the Duet Trial
Prevention of Complement Activation and Antibody Development: Results from the Duet Trial Jignesh Patel MD PhD FACC FRCP Medical Director, Heart Transplant Cedars-Sinai Heart Institute Disclosures Name:
More informationOUT OF DATE. Choice of calcineurin inhibitors in adult renal transplantation: Effects on transplant outcomes
nep_734.fm Page 88 Friday, January 26, 2007 6:47 PM Blackwell Publishing AsiaMelbourne, AustraliaNEPNephrology1320-5358 2006 The Author; Journal compilation 2006 Asian Pacific Society of Nephrology? 200712S18897MiscellaneousCalcineurin
More informationCostimulation blockade for prevention of
Costimulation blockade for prevention of acute GVHD Amelia Langston, MD Professor of Hematology & Medical Oncology Medical Director, Emory University BM & Stem Cell Transplant Center Emory University School
More informationCHAPTER 3 HEART AND LUNG TRANSPLANTATION. Editors: Mr. Mohamed Ezani Hj Md. Taib Dato Dr. David Chew Soon Ping
CHAPTER 3 Editors: Mr. Mohamed Ezani Hj Md. Taib Dato Dr. David Chew Soon Ping Expert Panel: Tan Sri Dato Dr. Yahya Awang (Chair) Mr. Mohamed Ezani Hj Md. Taib (Co-chair) Datin Dr. Aziah Ahmad Mahayiddin
More informationDSA Positive and then To biopsy or not?
DSA Positive and then To biopsy or not? Banff SCT 2017 29 March 2017 Peter Nickerson, MD, FRCPC, FCAHS Flynn Family Chair in Renal Transplantation Professor of Internal Medicine and Immunology Relevant
More information